Cargando…
Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis
BACKGROUND: Use of menopausal hormonal therapy (MHT)-containing estrogen and a synthetic progestin is associated with an increased risk of breast cancer. It is unclear if progesterone in combination with estrogen carries a lower risk of breast cancer. Limited data suggest differences between progest...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960754/ https://www.ncbi.nlm.nih.gov/pubmed/27456847 http://dx.doi.org/10.1186/s13643-016-0294-5 |
_version_ | 1782444580405248000 |
---|---|
author | Asi, Noor Mohammed, Khaled Haydour, Qusay Gionfriddo, Michael R. Vargas, Oscar L. Morey Prokop, Larry J. Faubion, Stephanie S. Murad, Mohammad Hassan |
author_facet | Asi, Noor Mohammed, Khaled Haydour, Qusay Gionfriddo, Michael R. Vargas, Oscar L. Morey Prokop, Larry J. Faubion, Stephanie S. Murad, Mohammad Hassan |
author_sort | Asi, Noor |
collection | PubMed |
description | BACKGROUND: Use of menopausal hormonal therapy (MHT)-containing estrogen and a synthetic progestin is associated with an increased risk of breast cancer. It is unclear if progesterone in combination with estrogen carries a lower risk of breast cancer. Limited data suggest differences between progesterone and progestins on cardiovascular risk factors, including cholesterol and glucose metabolism. Whether this translates to differences in cardiovascular outcomes is uncertain. We conducted a systematic review and meta-analysis to synthesize the existing evidence about the effect of progesterone in comparison to synthetic progestins, each in combination with estrogens, on the risk of breast cancer and cardiovascular events. METHODS: We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Scopus through 17 May 2016 for studies that enrolled postmenopausal women using progesterone vs. synthetic progestins and reported the outcomes of interest. Study selection and data extraction were performed by two independent reviewers. Meta-analysis was conducted using the random effects model. RESULTS: We included two cohort studies and one population-based case-control study out of 3410 citations identified by the search. The included studies enrolled 86,881 postmenopausal women with mean age of 59 years and follow-up range from 3 to 20 years. The overall risk of bias of the included cohort studies in the meta-analysis was moderate. There was no data on cardiovascular events. Progesterone was associated with lower breast cancer risk compared to synthetic progestins when each is given in combination with estrogen, relative risk 0.67; 95 % confidence interval 0.55–0.81. CONCLUSIONS: Observational studies suggest that in menopausal women, estrogen and progesterone use may be associated with lower breast cancer risk compared to synthetic progestin. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13643-016-0294-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4960754 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-49607542016-07-27 Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis Asi, Noor Mohammed, Khaled Haydour, Qusay Gionfriddo, Michael R. Vargas, Oscar L. Morey Prokop, Larry J. Faubion, Stephanie S. Murad, Mohammad Hassan Syst Rev Research BACKGROUND: Use of menopausal hormonal therapy (MHT)-containing estrogen and a synthetic progestin is associated with an increased risk of breast cancer. It is unclear if progesterone in combination with estrogen carries a lower risk of breast cancer. Limited data suggest differences between progesterone and progestins on cardiovascular risk factors, including cholesterol and glucose metabolism. Whether this translates to differences in cardiovascular outcomes is uncertain. We conducted a systematic review and meta-analysis to synthesize the existing evidence about the effect of progesterone in comparison to synthetic progestins, each in combination with estrogens, on the risk of breast cancer and cardiovascular events. METHODS: We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Scopus through 17 May 2016 for studies that enrolled postmenopausal women using progesterone vs. synthetic progestins and reported the outcomes of interest. Study selection and data extraction were performed by two independent reviewers. Meta-analysis was conducted using the random effects model. RESULTS: We included two cohort studies and one population-based case-control study out of 3410 citations identified by the search. The included studies enrolled 86,881 postmenopausal women with mean age of 59 years and follow-up range from 3 to 20 years. The overall risk of bias of the included cohort studies in the meta-analysis was moderate. There was no data on cardiovascular events. Progesterone was associated with lower breast cancer risk compared to synthetic progestins when each is given in combination with estrogen, relative risk 0.67; 95 % confidence interval 0.55–0.81. CONCLUSIONS: Observational studies suggest that in menopausal women, estrogen and progesterone use may be associated with lower breast cancer risk compared to synthetic progestin. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13643-016-0294-5) contains supplementary material, which is available to authorized users. BioMed Central 2016-07-26 /pmc/articles/PMC4960754/ /pubmed/27456847 http://dx.doi.org/10.1186/s13643-016-0294-5 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Asi, Noor Mohammed, Khaled Haydour, Qusay Gionfriddo, Michael R. Vargas, Oscar L. Morey Prokop, Larry J. Faubion, Stephanie S. Murad, Mohammad Hassan Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis |
title | Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis |
title_full | Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis |
title_fullStr | Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis |
title_full_unstemmed | Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis |
title_short | Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis |
title_sort | progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960754/ https://www.ncbi.nlm.nih.gov/pubmed/27456847 http://dx.doi.org/10.1186/s13643-016-0294-5 |
work_keys_str_mv | AT asinoor progesteronevssyntheticprogestinsandtheriskofbreastcancerasystematicreviewandmetaanalysis AT mohammedkhaled progesteronevssyntheticprogestinsandtheriskofbreastcancerasystematicreviewandmetaanalysis AT haydourqusay progesteronevssyntheticprogestinsandtheriskofbreastcancerasystematicreviewandmetaanalysis AT gionfriddomichaelr progesteronevssyntheticprogestinsandtheriskofbreastcancerasystematicreviewandmetaanalysis AT vargasoscarlmorey progesteronevssyntheticprogestinsandtheriskofbreastcancerasystematicreviewandmetaanalysis AT prokoplarryj progesteronevssyntheticprogestinsandtheriskofbreastcancerasystematicreviewandmetaanalysis AT faubionstephanies progesteronevssyntheticprogestinsandtheriskofbreastcancerasystematicreviewandmetaanalysis AT muradmohammadhassan progesteronevssyntheticprogestinsandtheriskofbreastcancerasystematicreviewandmetaanalysis |